Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access
Executive Summary
Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies
You may also be interested in...
Ipsen, Invida Group Sign Agreement To Commercialize Drugs In South-East Asia
SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region
Ipsen's First Focus Is Endocrinology As Firm Moves Toward Specialty Care
As Ipsen shifts away from an emphasis on primary care and toward specialty care therapies – a move straight out of Big Pharma’s playbook – endocrinology will become a pillar of its specialty care pipeline.
UCB’s New Strategy Takes SHAPE As GSK Buys Out Emerging Markets
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: